Percutaneous coronary intervention anaphylactoid reactions
Percutaneous Coronary Intervention Guidelines Microchapters |
PCI Approaches: |
---|
CAD Revascularization: |
Pre-procedural Considerations: |
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
Quality and Performance Considerations: |
Percutaneous coronary intervention anaphylactoid reactions On the Web |
American Roentgen Ray Society Images of Percutaneous coronary intervention anaphylactoid reactions |
FDA on Percutaneous coronary intervention anaphylactoid reactions |
CDC on Percutaneous coronary intervention anaphylactoid reactions |
Percutaneous coronary intervention anaphylactoid reactions in the news |
Blogs on Percutaneous coronary intervention anaphylactoid reactions |
Directions to Hospitals Treating Percutaneous Coronary Intervention |
Risk calculators and risk factors for Percutaneous coronary intervention anaphylactoid reactions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention: Anaphylactoid Reactions (DO NOT EDIT)[1]
Class I |
"1. Patients with prior evidence of an anaphylactoid reaction to contrast media should receive appropriate steroid and antihistamine prophylaxis before repeat contrast administration. [2][3][4][5](Level of Evidence: B)" |
Class III (No Benefit) |
"1. In patients with a prior history of allergic reactions to shellfish or seafood, anaphylactoid prophylaxis for contrast reaction is not beneficial. [6][7][8](Level of Evidence: C)" |
References
- ↑ Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=
ignored (help) - ↑ Klein LW, Sheldon MW, Brinker J, et al. The use of radiographic contrast media during PCI: a focused review: a position statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2009; 74: 728– 46.
- ↑ Levine GN, Kern MJ, Berger PB, et al. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med. 2003; 139: 123– 36.
- ↑ Tramer MR, von Elm E, Loubeyre P, et al. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. BMJ. 2006; 333: 675.
- ↑ Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med. 1985; 145: 2197– 200.
- ↑ Shehadi WH. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey. Am J Roentgenol Radium Ther Nucl Med. 1975; 124: 145– 52.
- ↑ Gill BV, Rice TR, Cartier A, et al. Identification of crab proteins that elicit IgE reactivity in snow crab-processing workers. J Allergy Clin Immunol. 2009; 124: 1055– 61.
- ↑ Swoboda I, Bugajska-Schretter A, Verdino P, et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol. 2002; 168: 4576– 84.